Long-Term Assets: The sum of all assets classified as non-current.
Relmada Therapeutics, Inc. (RLMD) had Long-Term Assets of $0.02M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-17.56M |
|
-- |
|
-- |
|
$18.22M |
|
$-18.22M |
|
$0.66M |
|
$-17.56M |
|
$-17.78M |
|
$-17.56M |
|
$-17.56M |
|
$-17.56M |
|
$-17.78M |
|
$-18.22M |
|
$-18.22M |
|
30.41M |
|
30.41M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$27.66M |
|
-- |
|
|
Long-Term Assets |
$0.02M |
$27.68M |
|
$5.23M |
|
-- |
|
$0.01M |
|
$5.24M |
|
$22.44M |
|
$22.44M |
|
$22.44M |
|
33.19M |
|
| Cash Flow Statement Financials | |
$-18.07M |
|
$15.36M |
|
$0.00M |
|
$3.86M |
|
$1.15M |
|
$-2.71M |
|
$4.48M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-78.25% |
|
-78.25% |
|
-63.44% |
|
-78.25% |
|
$0.68 |
|
$-0.59 |
|
$-0.59 |
|